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During the summer of 2002, Rio de Janeiro had a large
epidemic of dengue fever; 288,245 cases were reported. A
subset of 1,831 dengue hemorrhagic fever cases occurred.
In this study, performed in the first half of 2002, samples
from 1,559 patients with suspected cases of dengue infec-
tion were analyzed. From this total, 1,497 were obtained
from patients with nonfatal cases, and 62 were obtained
from patients with fatal cases. By the use of different meth-
ods, 831 (53.3%) cases, including 40 fatal cases, were con-
firmed as dengue infection. When virus identification was
successful, dengue virus type 3 (DENV-3) was obtained in
99% of cases. Neurologic involvement was shown in 1
patient with encephalitis, confirmed by the detection of
DENV-3 RNA in the cerebrospinal fluid. This explosive epi-
demic of DENV-3 was the most severe dengue epidemic
reported in Brazil since dengue viruses were introduced in
1986.
M
any factors were responsible for the resurgence of
epidemic dengue fever (DF) and dengue hemorrhag-
ic fever (DHF) in the final years of the 20th century.
Demographic and societal changes such as population
growth, urbanization, and modern transportation con-
tributed greatly to the increased incidence and geographic
spread of dengue activity (1). The prevalence of the dis-
ease is highest in tropical areas of Asia and the Americas,
with ≈50–100 million cases of DF and 250,000–500,000
cases of DHF occurring annually worldwide (1–3). 
The current epidemiologic situation in Latin America
resembles that in Southeast Asia some years ago, with the
cocirculation of multiple serotypes in many countries and
an increased number of DF and DHF cases. During 2002,
Latin American countries reported >1 million cases of DF
with >17,000 cases of DHF including 225 deaths (2). 
In Brazil, the introduction of dengue virus type 1
(DENV-1) and dengue virus type 2 (DENV-2) in the state
of Rio de Janeiro in 1986 and 1990, respectively, resulted
in the subsequent spread of these serotypes throughout the
country (4). The reintroduction of dengue virus type 3
(DENV-3) in the American continent in 1994 (5) and its
rapid spread to the Caribbean Islands in subsequent years
(6) resulted in intensified virologic surveillance in the
State of Rio de Janeiro, as a response to an imminent threat
of DENV-3 epidemics in Brazil. DENV-3 was first isolat-
ed in December 2000 in the municipality of Nova Iguaçu,
metropolitan region, from a patient with classic DF (7) and
initiated a period of cocirculation of DENV-1, DENV-2,
and DENV-3 in the state (8). In January 2002, a sudden
increase in the number of dengue cases occurred in suscep-
tible populations that had only experienced DENV-1 and
DENV-2 epidemics. In the first half of the year, the state
reported 288,245 dengue cases, including 1,831 DHF
cases and 91 deaths. The metropolitan region including
Rio de Janeiro city and surrounding counties reported
246,803 cases and 83 deaths. The number of DHF cases
exceeded the total number of cases reported in Brazil from
1986 to the time of the epidemic, and the annual incidence
of dengue infection in 2002 in the state reached 1,735 per
100,000 inhabitants (9). We describe laboratory and clini-
cal findings from 1,559 patients, including 62 who died
during the largest and most severe epidemic that has
occurred in Rio de Janeiro since DENV became endemic
in the country in 1986. 
Materials and Methods
Study Population
The 1,559 case-patients included in this study had acute
febrile illness with >2 of the following manifestations:
headache, retrobulbar pain, myalgia, arthralgia, rash, and
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outpatients from different healthcare centers, and the
remaining 62 were suspected dengue fatal cases in patients
hospitalized in private and public hospitals in the metro-
politan area of Rio de Janeiro city. The age range (1–73
years) was quite evenly distributed; 10.5% were 1–10
years of age, and 16.9%–19.9% of all patients were in each
10-year age group.
Laboratory Methods
Acute-phase serum specimens, cerebrospinal fluid
(CSF), and fresh tissues were stored at –70°C and conva-
lescent-phase serum specimens at –20°C until tested.
Dengue infections were confirmed by virus isolation or
viral RNA detection by reverse-transcriptase polymerase
chain reaction (RT-PCR), by immunoglobulin (Ig) M
and/or IgG seroconversion, or by the demonstration of
DENV antigen in formalized fixed autopsy tissues by
immunohistochemical tests.
Virus Isolation
Virus isolation was performed for all serum samples
obtained until day 7 after the onset of disease (n = 927), by
infection of clinical specimens into clone C6/36 of Aedes
albopictus cells. The virus isolates were typed by the indi-
rect fluorescent antibody test with serotype-specific mon-
oclonal antibodies (10).
RNA Extraction and RT-PCR
RT-PCR (11) was performed as a rapid molecular tool
to detect and type DENV only in acute-phase sera and
fresh tissues from patients who died, hospitalized patients,
and outpatients whose disease severity was characterized
by thrombocytopenia, hemorrhagic manifestations, or both
(n = 282). Viral RNA was extracted from clinical samples
(sera, CSF, and tissue) with QIAamp Viral RNA Mini Kits
(Qiagen, Inc., Valencia, CA, USA) according to the manu-
facturer’s protocol. 
Serology 
Dengue IgM-capture enzyme-linked immunosorbent
assay (ELISA) (PanBio, Brisbane, Australia) was per-
formed according to the manufacturers’instructions in sera
obtained after day 5 after onset of disease and in all sera
from patients who died (n = 1,060). An in-house IgM anti-
gen capture ELISA (MAC-ELISA) (12) was also per-
formed to confirm dengue infection in sera from patients
who died. 
IgG-ELISA was performed, as previously described
(13), in serum samples available from patients with fatal
outcomes (n = 37) and in paired serum samples from
patients with fatal cases (n =  88). According to the IgG-
ELISAcriteria, the immune response is defined as primary
when acute-phase serum samples obtained before day 5 of
illness have IgG antibody titers <1:160 and convalescent-
phase sera have titers <1:40,960. Infections are considered
secondary when IgG titers are >1:160 in the acute-phase
serum and >1:163,840 in convalescent-phase samples. 
Immunohistochemical Procedure
Sections of formalin-fixed, paraffin-embedded tissues
were processed by using the streptavidin-biotin method,
according to the manufacturer’s protocol (Kit LSAB,
DAKO, Carpinteria, CA, USA). Monoclonal antibodies
for DENV-1, -2, and -3 were provided by the Centers for
Disease Control and Prevention.
Results
Laboratory Findings 
DENV was isolated from 237 (25.6%) of 927 acute-
phase serum specimens injected into C6/36 cells and iden-
tified as DENV-3 (n = 234), DENV-1 (n = 2), and DENV-2
(n = 1). Of the 927 serum samples, 282 were submitted for
virus isolation and RT-PCR. RT-PCR identified 129
(45.7%) of 282 cases as DENV-3. Thus, the overall results
obtained with both methods showed that 321 (99.1%) of
324 viruses identified were DENV-3. A total of 171 sam-
ples were submitted for both MAC-ELISAand either virus
isolation or RT-PCR. When MAC-ELISA results were
added to the diagnostic algorithms, case confirmation
reached 53.3% (831/1,559) (Table 1).
Dengue infection was confirmed in 40 (64.5%) of 62
patients who died. In 21 of these cases, infection was con-
firmed by at least 2 methods employed as follows: 2 cases
by virus isolation and RT-PCR; 9 cases by MAC-ELISAand
RT-PCR; 6 cases by RT-PCR and immunohistochemistry; 2
cases by MAC-ELISA and immunohistochemistry; 1 case
by virus isolation, RT-PCR, and immunohistochemistry;
and 1 case by virus isolation, MAC-ELISA, and RT-PCR.
The male: female ratio was 1:1.08 in DENV-3 patients
and 1:1.6 when only fatal cases were considered. The age
range of patients who died was 7–65 years. A total of 103
clinical samples (serum or fresh tissues samples of liver,
spleen, lung, kidney, and brain) were available from the 62
patients with fatal outcome. In these samples, we were able
to detect viral RNA, by using RT-PCR, in 33 (32.0%) of
103 specimens. DENV-3 RNA was identified from the
CSF of 1 patient (Table 2). Of the 99 clinical specimens
injected into C6/36 cells, DENV-3 was recovered from 6
specimens; a total of 24 fatal cases were confirmed as
DENV-3 infection by using both methods (Table 2). 
Immunohistochemical procedures detected DENV anti-
gen in 48% of specimens from patients with fatal cases,
mainly in hepatocytes. Among all the tissues analyzed, the
liver was the site where DENV was most frequently
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histochemistry (Table 3). The pattern of immunoreactivity
in all tissues showed cytoplasmic granular positivity.
The histopathologic findings in patients with confirmed
fatal cases showed that the liver was the most affected
organ, with macro- and microvacuolization and discrete
lymphocytic infiltration of the periportal space. Focal
necrosis, swelling of hepatocytes, and colestasis were fre-
quently observed. Edema and congestion were the pre-
dominant findings in the brain. Microhemorrhagic foci
were also present; however, a marked inflammatory reac-
tion was not observed. Meningeal congestion was fre-
quent. Intraalveolar hemorrhaging was seen in the lungs,
associated with the inflammatory infiltration of lympho-
cytes. In the spleen, congestion of the paracortical zone
was the most frequent finding. 
IgG-ELISA was performed on 37 serum specimens
available from patients who died to characterize the
immune response, 20 (54.1%) cases were classified as pri-
mary infection, 9 (24.3%) cases as secondary, and 8
(21.6%) cases as inconclusive. In 88 nonfatal cases of con-
firmed DENV-3 infection, 49 (55.7%) were classified as
primary infection and 39 (44.3%) as secondary infection.
Clinical Findings
When stratified analysis was conducted on data from
the 297 DENV-3 patients who died (131 male and 166
female), confirmed by RT-PCR, virus isolation, or both,
the following signs and symptoms were noted: fever
(100.0%), headache (96.3%), myalgia (80.8%), prostration
(71.4%), nausea/vomiting (70.0%), retroorbital pain
(58.9%), and arthralgia (54.9%). Hypotension (8.8%) and
abdominal pain (1.7%) were also observed in some
patients with severe cases. Neurologic signs were observed
in 1.3%, and hepatic involvement was demonstrated by the
number of patients with jaundice (5.4%). Trombo-
cytopenia was noted in 6.1% of patients. The hemorrhagic
manifestations in 297 of these patients were metrorrhagia
(13.3%), epistaxis (3.7%), melena (5.1%), hematuria
(4.0%), hematemesis (2.7%), bleeding gums (1.3%),
hemoptysis (0.7%), and ecchymosis (1.0%). 
Discussion
During 2002, a total of 771,551 dengue cases were
reported in Brazil, mainly in the southeastern and north-
eastern regions. That number corresponded to 80% of
reported dengue cases in the Americas (http://www.
paho.org; 21 Nov 2002).
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14,391,282 inhabitants, is located in an area of 43,696,054
km2 on the coast of the southeast region of Brazil. Most of
the population (11,094,994) inhabit the greater metropoli-
tan region of the state, including the capital Rio de Janeiro
and another 18 surrounding municipalities. This region
caused 308,125 (87.5%) of 351,959 DENV-1 and DENV-
2 cases reported in the state in the last 15 years (9). 
The introduction of DENV-3 into Rio de Janeiro in 2000
placed the region at high risk for a new epidemic due to this
serotype, since the introduction of a new serotype into a
susceptible population with high mosquito densities may
produce a large epidemic after a lag period (14). Indeed, 1
year after the DENV-3 introduction, this serotype was
responsible for the most severe epidemic in the state’s his-
tory in terms of the highest number of reported cases, the
severity of clinical manifestations, and the number of con-
firmed deaths. In this DENV-3 epidemic, the number of
DHF/dengue shock syndrome (DSS) cases (1,831) and
deaths (91) exceeded the total number of DHF/DSS cases
(1,621) and deaths (76) in the entire country from 1986 to
2001 (15). The occurrence of 3 confirmed deaths in chil-
dren <15 years of age could represent a change in the epi-
demiologic scenario, since DHF/DSS cases in Brazil have
been observed almost exclusively in adults (16).
When we analyzed the clinical data on patients with
nonfatal cases, the frequency of fever, headache, and myal-
gias was similar to those observed during the DENV-1 epi-
demic in 1986 to 1987 (17); however, prostration,
hemorrhagic manifestations, and hypotension were
observed more often in the more recent DENV-3 epidem-
ic. Furthermore, prostration caused by DENV-3 infection
was previously described as a cause for hospital admission
during an epidemic in Queensland, Australia (18). Mild
and severe forms of the disease were also reported during
DENV-3 epidemics in New Caledonia and Tahiti, respec-
tively (19,20).
An increase in unusual manifestations was observed
during this epidemic, characterized by the incidence of cen-
tral nervous system (CNS) involvement and hepatitis.
Although CNS involvement has been previously reported
during dengue epidemics, including those in Brazil (21,22),
it increased during this epidemic, when many patients
reported dizziness. In 1 fatal case, this involvement was
confirmed by detecting DENV-3 RNA in CSF. Neurologic
disorders associated with dengue cases have been referred
to as dengue encephalopathy, attributed to immunopatho-
logic responses and not to CNS infection. However, isolat-
ing DENV-3 and detecting DENV-2 by using RT-PCR from
CSF provide evidence that DENV has neurovirulent prop-
erties and can cause encephalitis in both primary and sec-
ondary infections (23). Moreover, the breakdown of the
blood-brain barrier has been previously demonstrated in
fatal dengue cases (24). Data about transaminase levels
from dengue patients were not available; however, the
impact of DENV infection on liver functions could be
demonstrated by patients with jaundice. Alterations in lev-
els of aspartate aminotransferase and alanine aminotrans-
ferase were observed in 63.4% and 45% of dengue patients
in a study performed during a DENV-3 outbreak in the city
of Campos de Goytacazes in the same year (25). Transient
derangement of liver functions has been previously demon-
strated in dengue patients and in DHF patients with or with-
out hepatomegaly (26,27). In this study, hepatomegaly was
reported only in patients who died. A low rate of
hepatomegaly due to dengue infection was previously
reported in Manila; 1% of patients with confirmed cases
had this sign. These levels are considerably lower than the
levels observed in Bangkok (80%–90%) and Jakarta (49%)
(26). A study on clinical differences observed in patients
with dengue caused by DENV-3 showed that they had 3.06
times more risk for abdominal pain than patients with
DENV-1 and 6.07 times more risk for shock than patients
infected with DENV-2 (28).
A retrospective study of the patients who died (29) in
this epidemic showed that warning signs occurred in
88.1% of patients on hospital admission: hypotension
(59.5%), abdominal pain (35.7%), and preshock (35.7%).
During hospitalization, the proportion with hypotension
reached 75.6% and with shock, 61%. The World Health
Organization criteria for DHF were fullfilled by 35.5% of
the hospitalized patients. Death due to shock occurred in
57.8% of patients, cardiac failure in 17.8%, and massive
pulmonary hemorrhage and meningoencephalitis in 2
cases (29). 
Liver tissue was the most important tissue for virus
detection by using virus isolation, RT-PCR, or immunohis-
tochemistry. Recently, the liver was recognized as a major
target organ in the pathogenesis of DENV infection; the
active replication in hepatocytes (30,31) could explain
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patients who died was similar to that described in
Indonesia (32).
The increased mortality rate has already been related to
the general phenomenon of increased dengue incidence
and severity. The reintroduction of DENV-3 in Puerto Rico
and Queensland did not result in death (14,18); however,
in Jakarta the DENV-3 fatality rate was nearly 3 times
higher than the fatality rate observed for the other
serotypes (33).
In this study, the disease severity and the occurrence of
deaths resulting from primary infections could be partially
explained by the virulence of the DENV-3 strain. Analysis
of the partial nucleotide sequence of the genome showed
that Brazilian DENV-3 belongs to genotype III (Sri
Lanka/India), similar to the strains currently circulating on
the American continent (34). Previous studies have shown
that this genotype caused DHF epidemics in Sri Lanka and
India and was associated with DHF cases in Mexico (35).
Fatal cases resulting from dengue primary infections were
described before DENV-3 was introduced in Brazil (36),
although the largest number of DHF/DSS cases occurring
in the state were due to secondary DENV-2 infections
(Southeast Asia-Jamaican genotype) (16). These findings
showed that some DENV strains can be more virulent than
others and that antibody-dependent enhancement alone
does not explain all cases of severe disease (33,37–39).
Genotyping studies performed in Sri Lanka and French
Polynesia showed that viral strains in themselves are an
important risk factor for DHF/DSS (20,40). 
The scenario of dengue in Brazil indicates that more
emphasis should be placed on efforts to control the vector.
An active epidemiologic surveillance laboratory should be
supported, and a clearer understanding of the epidemiolog-
ic characteristics of dengue transmission is required.
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